The tumor suppressor p53 is the most frequently mutated gene in human cancer. In vivo models have been generated using knock-in alleles in which missense mutations are introduced that mimic the kinds of mutations found in human cancers, or that abolish specific p53 functions. Critically, these studies examine the in vivo and physiological functions of p53. Studies indicate that p53 missense mutations in the DNA-binding domain identical with those inherited in the Li-Fraumeni syndrome, have distinct properties. Studies in mice with mutants that separate cell-cycle arrest and apoptosis functions of p53 show delayed onset of tumor development, suggesting that both p53 functions are crucial for suppressing tumors. Mice with mutations at post-translational modification sites exhibit subtle effects on p53 activity and tumor development, indicating a fine-tuning mechanism of p53 activity in vivo. Importantly, each mutant mouse has a distinct phenotype, suggesting diverse and exquisite mechanisms of p53 regulation in different environments, different tissues and different genetic backgrounds. The generation of these mutant p53 knock-in mice has laid the groundwork for future studies to elucidate the in vivo physiological function of mutant p53 and to examine cooperating effects in combination with other alterations.
Introduction
p53 is a transcription factor that activates numerous downstream target genes that initiate cell-cycle arrest, apoptosis and senescence. The clinical observation that p53 is the most frequently mutated tumor suppressor underscores the importance of maintaining p53 activity in cells (Vogelstein and Kinzler, 1992; Levine, 1993) . Unlike other tumor suppressors, however, most p53 mutations are missense mutations in the DNA-binding domain rather than gene deletion (Bartek et al., 1991; Hollstein et al., 1991) . This observation raises the question: are tumors with p53 mutations at a distinct advantage than those with p53 deletions? These mutations, at a minimum, disrupt p53's ability to transactivate downstream target genes. In vitro and in vivo studies show that some mutant p53 proteins have oncogenic potential, called gain of function (Roemer, 1999; Deppert et al., 2000; van Oijen and Slootweg, 2000; Cadwell and Zambetti, 2001) . Clinically, patients with some p53 missense mutations have a worse prognosis than patients with deletion of p53, supporting the gainof-function hypothesis (Roemer, 1999; Lai et al., 2000; Powell et al., 2000; Skaug et al., 2000; Iacopetta, 2003) . To address mechanisms of gain of function in vivo, two groups have recently characterized knock-in mice with p53 'hot spot' missense mutations Olive et al., 2004) . These mouse models support a gainof-function phenotype under physiological conditions. These new models resemble the mutations in p53 in Li-Fraumeni syndrome and will be invaluable in further studies of tumor initiation, progression and metastases.
The regulation of p53 activity is crucial for homeostasis and tumor suppression because too much p53 often leads to cell death, whereas not enough results in tumor development. Normally, wild-type p53 is unstable with a half-life o30 min, mainly owing to interactions with the E3 ubiquitin ligase, Mdm2, that degrades p53 (Delmolino et al., 1993; Gu et al., 2000) . Various signals modify p53 post-translationally (phosphorylation, ubiquitination, acetylation, sumoylation, neddylation and methylation) and regulate p53 activity as a transcription factor (Lavin and Gueven, 2006) . For example, phosphorylation at serines 15 or 20 disrupts the p53-Mdm2 interaction, resulting in stabilization and activation of p53 (Shieh et al., 1997; Chehab et al., 1999) . Acetylation at the carboxyl-terminal lysines by CBP/p300 or P/CAF increases sequence-specific DNA-binding activity (Gu and Roeder, 1997; McKinney et al., 2004) . Knock-in mice with serine-to-alanine or lysine-to-arginine substitutions show subtle phenotypes. In contrast, mice harboring a mutation that disrupts the transcriptional activity of p53 and its interaction with Mdm2 are not viable. These results strongly suggest that p53 stability and activity are finely tuned by post-translational modifications.
Other p53 mouse models were generated to examine the importance of apoptosis and cell-cycle arrest on tumor development. Mice inheriting a p53 R172P mutation, which mimics a rare mutation found in human cancers, retain only a partial cell-cycle arrest function and show a delayed tumor onset when compared to p53-null mice . Tumors from these mice exhibit a diploid chromosome number suggesting that chromosome stability is essential for suppressing early tumor development in the absence of an apoptotic function of p53. Moreover, mice with a small p53 deletion that retains only a partial apoptotic response also exhibit delayed tumor onset suggesting that both activities of p53 are important in in vivo tumor suppression (Toledo et al., 2006) .
Thus, the characterization of mice with missense mutations at the endogenous p53 locus is the best approach to dissect the physiological functions of both wild-type and mutant p53 as well as to explore the events that contribute to human cancers.
Gain-of-function p53 hot spot mutations
Approximately 80% of Li-Fraumeni syndrome patients with p53 mutations inherit a missense mutation (Malkin et al., 1990; Srivastava et al., 1990; Bartek et al., 1991; Hollstein et al., 1991) . To address the physiological relevance of these missense mutations, several laboratories attempted to generate mouse models for three of the hot spot mutations: p53R172H (175 in human), p53R270H, (273 in human) and p53P275S (278 in human) (Liu et al., 2000; de Vries et al., 2002) . These initial studies failed to recapitulate the human disease in mice.
ES cells with one targeted allele of either the p53
or the p53 þ /P275S mutation gave rise to weak chimeras that never went germline (de Vries et al., 2002) . Analyses of heterozygous mutant ES cells and thymocytes obtained by Rag2-null blastocysts complementation assays show delayed transcriptional activation of p53 downstream target genes upon g-irradiation and a compromised apoptotic response after doxorubicin treatment. These results strongly suggest that mutant p53 can inhibit the function of wild-type p53. Thus, the presence of mutant p53 in ES cell cultures and its inhibition of wild-type p53 may have led to aneuploidy, a condition observed in cells lacking p53, and subsequently failure to generate mice.
In the p53R172H study, the targeted allele contains an additional deletion of a G nucleotide at a splice junction, leading to hypomorphic expression of the p53R172H mutant (this allele is referred to as p53 R172HDg ) (Liu et al., 2000) . The hypomorphic nature of this mutation allowed chromosome stability in culture and generation of mice. Nevertheless, mice heterozygous for p53 R172HDg (mixed C57BL/6-129/Sv background) develop more carcinomas and show a higher frequency of metastasis than p53 þ /À mice. Thus, these initial studies were the first to suggest additional functions for mutant p53 when expressed from the endogenous locus (Figure 1) .
To address the molecular mechanisms of the gain-offunction phenotypes in vivo, two groups finally generated mice containing p53 missense mutations at codons 172 and 270 on different genetic backgrounds Olive et al., 2004) . This time both laboratories incorporated either a lox-stop-lox or a neo cassette that prevents expression of the mutant p53 protein in culture, but could be removed in vivo via Cre recombination.
By comparing phenotypes of mice with p53 mutant or null alleles, heterozygous mutant mice with p53 mutations at codons 172 or 270 exhibit more aggressive and metastatic tumor phenotypes in both the C57BL/6 and 129S 4 /SvJae backgrounds than p53 þ /À mice Olive et al., 2004) . Additionally, on the 129S 4 / SvJae background, both p53
and p53 þ /R270H mutant mice exhibit increased numbers of carcinomas and B-cell lymphomas compared to p53 þ /-mice (Olive et al., 2004) . Moreover, p53 þ /R172H mice develop more osteosarcomas than p53 þ /-or p53 þ /R270H mice, and p53 þ /R270H mice produce carcinomas at higher frequency compared to other genotypes on the 129S 4 /SvJae background. p53 þ /R172HDg mice on a mixed C57BL/6-129SV background also show an increased number of carcinomas (Liu et al., 2000) . In contrast, on the C57BL/6 background, no differences in tumor spectra are observed between p53 þ /R172H and p53 þ /-mice. Together, these results clearly indicate that mutant p53 shows a gain-of-function phenotype in vivo and that both the type of mutation and the genetic background affect the tumor phenotypes.
The availability of these mice prompted studies to determine the mechanism of gain of function by mutant p53. Previous biochemical experiments had shown that the p53 family members, p63 and p73, interact with mutant p53, but not with wild-type p53, and importantly that the interaction inhibits the function of p63 and p73 as transcription factors (Di Como et al., 1999; Gaiddon et al., 2001; Strano et al., 2002) . To test the biological significance of these interactions, metastatic tumor cell lines from p53 þ /R172H mutant mice were established, and these show that endogenous mutant p53 interacts with both p63 and p73 Olive et al., 2004) . Functionally as well, mutant p53 inactivates p63 and p73, and down modulation of p63 and p73 by specific siRNAs in p53-null mouse embryo fibroblasts (MEFs) increases their transformation potential equal to that seen in p53 R172H/R172H MEFs. These data suggest that loss of p63 and p73 activity contributes to the gain-of-function phenotype of mutant p53. The role of p63 and p73 in tumor suppression was also tested in vivo . Compound knockout mice, p53
develop metastatic tumors at high frequencies, a phenotype reminiscent of mutant p53 mice, strongly supporting the hypothesis that p63 and/or p73 are functionally inactivated by mutant p53 in the metastatic phenotype of p53 mutant mice (Iwakuma et al., 2005) .
In addition to gain-of-function phenotypes, mutant p53 exhibits dominant-negative effects on apoptosis induced by g-irradiation. The degree of apoptosis in thymocytes from heterozygous mutant p53 mice is intermediate to that of thymocytes from p53 þ /À and p53 À/À mice suggesting a partial dominant-negative effect (Olive et al., 2004) . Further, apoptosis of the developing hypothalamus in p53
mice after g-irradiation is similar to that of p53 null mice . These results suggest that mutant p53 has dominant-negative activities and as such inactivates the ability of wild-type p53 to transactivate apoptotic target genes. However, in at least one case, mutant p53 does not inactivate wild-type p53. In this case, a single mutant p53 allele cannot rescue the p53-dependent phenotype of Mdm2-null mice. These data raise the tantalizing suggestion that mutant p53 functions as a dominant negative only in response to stress such as ionizing radiation.
An initial characterization of tumors from p53 mutant mice revealed some additional interesting results. Most, but not all, tumors from heterozygous and homozygous p53 R172H and p53 R270H mice exhibit high levels of p53 protein. In contrast, the surrounding normal tissues of the same mice do not display increased levels of p53 Olive et al., 2004) . These observations suggest that mutant p53 is inherently unstable and that tumor-specific changes stabilize mutant p53. These observations further led us to hypothesize that gainof-function and dominant-negative functions result from stabilization of mutant p53. In support of this hypothesis, the survival curves of p53 þ /À and heterozygous mutant p53 mice are identical, presumably because an unstable mutant p53 does not exhibit gainof-function or dominant-negative properties. Subsequent stabilization of mutant p53 in tumors may cause more severe tumor phenotypes in the heterozygous mutant mice than the p53 þ /À mice. Further studies are required to understand the mechanisms of gain-offunction and dominant-negative functions of mutant p53.
p53 mutants that separate cell-cycle arrest and apoptosis functions
The importance of functions other than apoptosis in p53-mediated tumor suppression has also been studied in vivo. The p53R175P mutant shows a partial loss of function as it could transactivate p21, but fails to induce apoptosis (Crook et al., 1994; Ludwig et al., 1996; Rowan et al., 1996) . To decipher the functional importance of cell-cycle arrest in absence of p53-dependent apoptosis on spontaneous tumorigenesis, mice carrying this mutation (172 in the mouse) were Crippling p53 activities via knock-in mutations T Iwakuma and G Lozano generated (p53R172P) . Detailed characterization of mice and MEFs supports the initial distinction between p53 functions. p53 R172P/R172P cells retain a partial cell-cycle checkpoint function and induce p21 expression after g-irradiation, but lack p53-dependent apoptosis . Importantly, mice homozygous for the p53 R172P allele show delayed onset of tumorigenesis as compared to p53-null mice, suggesting that p53-dependent apoptosis is not the only requirement for suppression of tumor development. The p53 R172P/R172P mice eventually develop lymphomas and sarcomas that retain a diploid number of chromosomes. In contrast, tumor cells from p53-null mice show aneuploidy and abnormal numbers of centrosomes. Therefore, the ability of the mutant p53R172P to induce a partial cell-cycle arrest and retain chromosomal stability is crucial for suppressing early onset of tumor development.
Another important domain at the amino-terminus of p53 is the proline-rich domain (PRD). To address the physiological relevance of PRD, mice were generated with deletion of the PRD spanning amino acids 77-89 (p53DP) (Toledo et al., 2006) . Analyses in MEFs show that p53DP exhibits a deficient cell-cycle arrest response but retains a proapoptotic response. Studies using p53 DP/DP MEFs also reveal that p53DP is a less efficient transactivator, is more sensitive to Mdm2-mediated degradation, and is bound less efficiently to the responsive elements of p21 and mdm2 genes than wild-type p53. p53 DP/DP mice show delayed tumorigenesis compared to p53-null mice. Furthermore, using oncogene-induced tumor formation in a xenograft model, p53DP slightly reduces tumor size compared to the p53-null allele. To evaluate the in vivo function of the p53DP allele, crosses to determine the ability to rescue the p53-dependent Mdm2-null and Mdm4-null lethal phenotypes were performed (Montes de Oca Luna et al., 1995; Parant et al., 2001) . Interestingly, p53 DP/DP rescues the Mdm4-null but not the Mdm2-null embryonic lethality.
Mdm4
À/À p53 DP/DP MEFs show increased p53 activity and decreased transformation potential in a xenograft model, providing evidence that the specific inhibition of Mdm4 can enhance tumor suppression effects. Thus, in vivo studies of p53R172P and p53DP mice clearly indicate that both cell-cycle arrest and apoptosis functions of p53 are required for suppressing tumor development in vivo.
A p53 mutant lacking transcriptional activity that also cannot interact with Mdm2
To address the in vivo significance of the transactivation function of p53, mice with glutamine and serine mutations at leucine 25 and tryptophan 26 (equivalent to human 22 and 23), respectively (referred to as p53QS mutant) were generated . This p53 mutant cannot activate transcription, but unfortunately nor can it bind Mdm2. Mice heterozygous for p53QS are early embryonic lethal. Consistent with previous studies, the mutant p53 is more stable than wild-type p53 most likely owing to lack of interaction with Mdm2 (Lin et al., 1994; Uesugi and Verdine, 1999) . Stable mutant p53 may bind and inhibit the function of numerous other proteins that bind p53, causing the embryonic lethality. Additional studies using MEFs reveal that the p53QS mutant retains some transactivation function. p53QS can activate the bax gene, but not most of the canonical p53 target genes such as p21 and perp. The combination of partial activities coupled with increased stability may explain the adverse effects of this mutation on development . Further studies using this mouse will provide a better understanding of p53 activities.
p53 post-translational modifications: minor role in tumorigenesis p53 is an unstable protein regulated by post-translational modifications. Genotoxic or oncogenic stresses stabilize p53 through post-translational modifications such as phosphorylation. Phosphorylation at the aminoterminus disrupts interaction with Mdm2 and phosphorylation at the carboxyl terminus increases oligomerization (Hupp and Lane, 1994; Sakaguchi et al., 1997; Shieh et al., 1997; Chehab et al., 1999; Craig et al., 1999; Unger et al., 1999a) . Lysines at the carboxyl terminus are also modified by ubiquitination, acetylation, neddylation, sumoylation and methylation (Gu and Roeder, 1997; Gostissa et al., 1999; Rodriguez et al., 1999 Rodriguez et al., , 2000 Chuikov et al., 2004; Harper, 2004; Xirodimas et al., 2004; Friedler et al., 2005) .
To address the importance of serine 15 (18 in mouse) phosphorylation in a physiological context, an alanine substitution was made at the endogenous p53 locus (S18A) (Chao et al., 2000; Sluss et al., 2004) . Homozygous S18A mice develop normally and are not tumor prone. S18A mutation in MEFs does not alter protein stability, proliferation rate, G1 arrest function after DNA damage and suppression of cell immortalization, suggesting wild-type function in MEFs. However, the mutant p53 in lymphocytes from the homozygous S18A mice shows a compromised p53-mediated apoptotic response. These results indicate that phosphorylation of serine 18 regulates p53 apoptotic functions and that phosphorylation of this site is not required for p53 suppression of spontaneous tumor development (Sluss et al., 2004) .
Serine 20 (23 in mouse) is within the p53 transactivation domain that interacts with the p53-negative regulator, Mdm2 (Kussie et al., 1996; Uesugi and Verdine, 1999) . Several studies suggest that phosphorylation of serine 20 plays a role in stabilizing p53 after DNA damage (Chehab et al., 1999; Craig et al., 1999; Shieh et al., 1999; Unger et al., 1999b) . To investigate the physiological role of this phosphorylation event, mice containing an alanine substitution were made (S23A) (Wu et al., 2002; MacPherson et al., 2004) .
Analyses of ES cells and MEFs reveal no effects on
Crippling p53 activities via knock-in mutations T Iwakuma and G Lozano p53S23A stability, transcriptional activity and cell-cycle checkpoint function after DNA damage (Wu et al., 2002; MacPherson et al., 2004) . However, in thymocytes and developing cerebellum of the S23A mice, p53 stabilization is decreased and apoptotic response is partially impaired following g-irradiation (MacPherson et al., 2004) . Importantly, homozygous S23A mice are tumor prone compared to wild-type mice. Most tumors develop after 1 year and are of the B-cell lineage. These results suggest that phosphorylation of serine 23 in the mouse plays an important role in p53 stabilization, apoptosis and suppression of tumor development in a cell-type-dependent manner. Phosphorylation of both serines 15 and 20 in human p53 occurs simultaneously after various DNA damage signals, suggesting that the two phosphorylation events might have synergistic roles in activating p53 responses (Takai et al., 2002; Wu et al., 2002; Kurz et al., 2004; Chao et al., 2006) . To test this idea in vivo, mice harboring mutations of both serines 18 and 23 to alanines (S18/23A) in the endogenous mouse p53 locus were generated (Chao et al., 2006) . In MEFs, serines 18 and 23 do not have obvious functional synergy in p53 stabilization and activation. However, using 3T3 assays, S18/23A MEFs undergo spontaneous immortalization more easily than wild-type MEFs, but not as easily as p53-null MEFs. Additionally, S18/23A thymocytes are essentially resistant to p53-dependent apoptosis. Consistent with this observation, S18/23A protein level is reduced and expression of several p53 target genes is severely impaired in thymocytes after DNA damage. S18/23A homozygous mice are tumor prone and develop a variety of tumors after 1 year. Lymphomas of the spleen and lymph node are more common than thymic lymphomas. A functional test of impaired p53 activity is a cross with Xrcc4-null mice. Xrcc4 is critical for nonhomologous end-joining pathway (Donehower et al., 1995) . Xrcc4 loss in mice results in extensive DNA damage, accompanied by massive neuronal apoptosis and embryonic lethality, a phenotype that is p53 dependent (Gao et al., 2000) . Homozygosity of the S18/23A allele also rescues the Xrcc4-null embryonic lethality. Thus, S18/23A mutation essentially abolishes the p53-dependent apoptosis in the developing neurons in the presence of DNA damage. Although Xrcc4
S18/23A mice are born alive, they are not highly tumor prone like Xrcc
À/À mice, and instead exhibit developmental defects typical of accelerated ageing. Possibly S18/23A retains certain wild-type p53 functions. In summary, the phenotypes of S18/23A mice are more severe than those of S18A or S23A mice, indicating that phosphorylation of serines 18 and 23 is critical for activating p53-dependent apoptosis and suppression of spontaneous tumor development.
Whereas modifications at the amino terminus disrupt the interaction of p53 with Mdm2, modifications at the carboxyl-terminal basic domain are thought to alter the p53 conformation, leading to enhanced sequence-specific DNA binding and transcriptional activities of p53 Anderson, 2000, 2001) . In this basic domain, serine 392 in human (389 in mouse) is phosphorylated only by exposure to ultraviolet (UV) but not g-irradiation (IR) (Kapoor and Lozano, 1998; Lu et al., 1998) . Phosphorylation of this serine results in stabilizing the p53 tetramer and enhancing sequencespecific DNA-binding ability of p53 in vitro (Hupp and Lane, 1994; Sakaguchi et al., 1997) . Other studies also support the importance of phosphorylation at this serine in cell-cycle arrest and apoptosis functions of p53 (Milne et al., 1992; Hao et al., 1996; Achison and Hupp, 2003) . To enable in vivo functional analyses of this phosphorylation site, mice were generated containing a serine-toalanine substitution at serine 389 in the endogenous p53 locus (S389A) (Bruins et al., 2004) . Homozygous mutant mice are viable and normal with no increase in spontaneous tumor development. The alteration results in moderate reduction of protein stability and DNAbinding activity of p53 after UV irradiation. Expression of some p53 downstream target genes after UV treatment is also slightly impaired in S389A MEFs compared to those with wild-type p53 (Bruins et al., 2004; Iwakuma et al., 2004) . Apoptotic response of S389A MEFs is partially impaired after UV irradiation, but not after g-irradiation. Importantly, the mutant mice are more susceptible to UV-induced skin tumor development compared to wild-type mice, suggesting that the phosphorylation of serine 389 plays a role in UVinduced apoptosis and tumor suppression.
The p53 protein is degraded mainly via the ubiquitination pathway in which the negative regulator Mdm2 is the E3 ubiquitin ligase (Iwakuma and Lozano, 2003) . Six lysine residues at the carboxyl terminus of human p53 (Lys370, 372, 373, 381, 382 and 386) are implicated as sites for ubiquitination by Mdm2 (Rodriguez et al., 2000) . In vitro studies have revealed that these lysines are also modified through acetylation (Lys370, 372, 373, 381 and 382) (Gu and Roeder, 1997; Friedler et al., 2005) , methylation (Lys372) (Chuikov et al., 2004) , sumoylation (Lys382) (Gostissa et al., 1999; Rodriguez et al., 1999) and neddylation (Lys370, 372 and 373) (Harper, 2004; Xirodimas et al., 2004) . These modifications alter p53 transcriptional activity either positively or negatively. The choice of which lysine is modified by what mechanism remains unclear. To further study the physiological roles of the post-translational modifications at the carboxyl-terminal lysine residues in regulation of p53 stability and activity, two groups generated mutations of all six lysines (K) to arginines (R) (Feng et al., 2005; Krummel et al., 2005) . The K6R mutations at codons 367, 369, 370, 378, 379 and 383 of mouse p53 were introduced into ES cells by homologous recombination at the endogenous mouse locus (Feng et al., 2005) . K6R mutant exhibits normal protein stability, but partially impaired transcriptional ability, on some target genes after DNA damage in ES cells and thymocytes, but not in MEFs. These results suggest that ubiquitination of these six lysine residues are not required for efficient p53 degradation and that posttranslational modifications at the carboxyl-terminal lysines play a role in activating p53 activity on certain target genes after DNA damage. Mice with lysine-toarginine mutations at the same six lysines plus one additional lysine at codon 384 which does not have a corresponding lysine in human p53 (7KR) were also generated (Krummel et al., 2005) . Mice homozygous for 7KR are born at the appropriate Mendelian ratio and are phenotypically normal. Analyses of 7KR MEFs and thymocytes reveal no difference in protein half-life, cellcycle checkpoint and apoptosis functions. However, a significant difference is seen in response to g-irradiation in thymocytes but not in MEFs. Upon irradiation, the 7KR mutant accumulates more rapidly and transactivates target genes more efficiently than wild-type p53. Importantly, using 3T3 assay, 7KR MEFs exhibit more resistance to spontaneous transformation than wild-type MEFs, suggesting a significant contribution of these lysines to tumor suppression. Thus, the carboxylterminal modifications at lysines are not essential but contribute to the fine-tuning of p53 activity in vivo. Minor changes in p53 level and activity by the carboxylterminal lysine modifications may act as modifiers of a tumor phenotype.
Human p53 knock-in (Hupki) mice
Most of p53 mutations of human cancer are present in the DNA-binding domain. Although mouse p53 is highly homologous to human p53 especially in the DNA-binding domain (91%), the nucleotide sequences in this domain differ at 15% of base residues between human and mouse. This sequence difference can cause different mutational spectra induced by mutagens. In fact, specific mutagen-induced mutations in the p53 gene in tumors do not accumulate at precisely the same sites in mice and in humans (Dumaz et al., 1997) .
To explore carcinogen-specific human p53 mutation patterns experimentally, Hollstein's group generated a human p53 knock-in (Hupki) mouse in which the mouse p53 DNA-binding domain was replaced with that of human p53 (Luo et al., 2001b) . The modified p53 gene is expressed at physiological levels and the Hupki protein exhibits various cellular functions similar to murine p53. Importantly, mice homozygous for this mutation are not tumor prone, suggesting that the human sequences are functional. The efficacy of this mouse model is proven by the experimental result that epidermal cells of the Hupki mice accumulate UV photoproducts at the same locations as human p53 gene upon UV-B irradiation (Luo et al., 2001a) . Another validation of Hupki mice was performed using Hupki MEFs (Liu et al., 2005) . When cells are exposed to a major tobacco carcinogen, benzo(a)pyrene, the Hupki MEFs display similar p53 mutation profiles to that seen in human lung cancer. Thus, this mouse model is invaluable to examine mutation patterns of the human p53 gene induced by carcinogens. Additionally, this mouse model will be suitable for evaluating efficacy of drugs that are designed to modify the activity of human p53 protein for the clinical usage.
Conclusion
Mouse models of cancer have proven useful in deciphering some of the mechanisms of tumor development. In particular, the studies of p53 mutant mice clearly demonstrate contributions of gain-of-function and dominant-negative properties of mutant p53 to cancer progression. These data hint at the requirement that mutant p53 needs to become stable to exhibit its dominant-negative and gain-of-function activities. Importantly, mutations in the DNA-binding domain that mimic those found in human cancers, result in pronounced tumor phenotypes. Differences in tumor spectra between p53 mutants are clear. Additionally, different tumor phenotypes in different strains with the same mutation suggest an important role of genetic background in modifying the effects of mutant p53. On the other hand, alterations of amino acids that are posttranslationally modified and have not been identified in human tumors play a minor role in tumor development. These analyses have raised numerous questions that will be addressed in the future. Combining p53 mutant alleles with other tumor models will further dissect the signaling pathways that synergize in tumor development.
